About ADEL

ADEL, Inc. was established in 2016 and is a SPIN-off company at Asan Hospital in Ulsan Medical School,
aimed at developing neuropathic treatments and diagnostic systems such as Alzheimer’s disease.


We dream of a world
without dementia

ADEL, Inc.

ADEL, Inc.
Seung-Yong Yoon
Establishment date
November 10, 2016
Business Areas
Alzheimer's disease & Dementia treatment and diagnostic method
Dep of Brain Science, AMC, 88, Olympic-ro 43-gil, Songpa-gu, Seoul
Seongnae Lab:
HANS building 3F & 5F, 90, Pungseong-ro, Gangdong-gu, Seoul
Gwanggyo Lab:
A-711&712, 338, Gwanggyojungang-ro, Suji-gu, Yongin-si, Gyeonggi-do
Number of employees
20 people (October 2023)
R&D personnel
15 people (October 2022)


Seung-Yong YoonMD, PhD.

  • CEO of ADEL
  • Chief Professor at the Department of Brain Science, Asan Medical Center, University of Ulsan College of Medicine
  • Director of Brain Neuroscience Research Team, Asan Institute for Life Sciences
  • Bachelor's, Master's, and Doctorate degrees in Medicine from Ulsan University School of Medicine
  • 20 years of experience in Alzheimer's disease research and development
  • Author of over 70 SCI papers and holder of over 10 patents
  • Career spanning the entire research and development process (Basic-CMC-Preclinical-Clinical)
  • Success in technology transfer and collaborative research commercialization



  • 2023

    • US FDA Ph1 IND (Y01)
    • Addition of pipelines
  • 2020

    • Series B
    • Contract with Co-development partner (Oscotec, Inc)
  • 2018

    • Series A
  • 2016

    • ADEL, Inc. establishment